2022 Fiscal Year Final Research Report
Establishment of a novel nuclear medicine diagnostic method of drug-metabolizing enzyme activity for personalization and optimization of drugs
Project/Area Number |
19K17194
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52040:Radiological sciences-related
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | 薬物代謝酵素 / CYP / CYP2D6 / CYP3A4 / メキタジン |
Outline of Final Research Achievements |
In this study, we considered the optimization of drug therapy in consideration of individual differences in drug metabolism to be an important issue, and developed an imaging method to evaluate CYP2D6 activity. Using radioiodine-labeled mexitazine (I-IMQ) and 18F-labeled mexitazine (18F-FMMQ) and radioiodine-labeled O-desmethylvenlafaxine (I-ODV), SPECT and PET for quantitative evaluation of CYP2D6 alone and CYP2D6 and CYP3A4 metabolic activities Imaging methods have been established. By analyzing the biliary excretion kinetics of these imaging agents, CYP activity can be evaluated and contribute to the development of drug treatment strategies appropriate for individual patients.
|
Free Research Field |
放射線科学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究では、核医学画像診断薬を用いた新たな手法による薬物代謝酵素活性定量法の可能性を示した。CYP2D6およびCYP3A4の活性を評価するための画像診断薬の開発を行ったことにより、抗うつ薬や抗精神病薬などの精神神経疾患治療薬を含む、これらの酵素によって代謝される薬剤において、個々の患者の薬剤治療効果予測が可能になる。この手法は患者の個別化医療の基盤形成において重要な役割を果たし、薬剤の適切な投与量や投与間隔の決定において貴重な情報を提供することが期待できる。
|